Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Gemcitabine (Primary) ; Ribociclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 Planned initiation date changed from 10 Aug 2017 to 10 Oct 2017.